Vance Fowler, MD
Enriched profileFlorence McAlister Distinguished Professor of Medicine, Division of Infectious Diseases, Duke University School of Medicine · Duke University
Vance Fowler is Florence McAlister Distinguished Professor of Medicine, Division of Infectious Diseases, Duke University School of Medicine at Duke University. OpenAlex indexes 698 publications with 58,472 citations (h-index 114); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Infectious Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Vance Garrison Fowler Jr., MD, is Florence McAlister Distinguished Professor of Medicine, Division of Infectious Diseases, Duke University School of Medicine. The public record shows 698 publications with 58,472 citations (h-index 114), centered on Antimicrobial Resistance in Staphylococcus, Infective Endocarditis Diagnosis and Management, Bacterial Identification and Susceptibility Testing. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 6 companies, 8 NIH-funded awards (1999–2026).
- Most recent indexed publication: 2026 · Science advances
- Top research focus: Antimicrobial Resistance in Staphylococcus
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 33 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 404.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial
Sponsor: Duke University
Industry payments
Updated 27 Aug 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- IntervascularProgram year20251 payment
- La Jolla Pharmaceutical CompanyProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
88.9%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor25%Triumeq58%Descovy42%Part D<11 patientsProtease Inhibitor20.8%Prezcobix100%Part D<11 patientsMetabolism & gastrointestinal
11.1%Serotonin-3 Receptor Antagonist11.1%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
8 NIH research awards on record, funded 1999–2026 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study.
Antimicrobial agents and chemotherapy
Article2026 - Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes.
Clinical infectious diseases
Article2026 - Escherichia coli ST131 Drives Carbapenem Use for E. Coli Bloodstream Infections.
Clinical infectious diseases
Article2026 - Methicillin-resistant and susceptible Staphylococcus aureus: tolerance, immune evasion and treatment.
Nature reviews. Microbiology
Review2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04
- 05Infective Endocarditis1,701 citations2005
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/vance-fowler-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Vance-Fowler
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/vance-fowler-1435436
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
arlg.org/vance-fowler-honored-with-distinguished-professorship-from-duke-school-of-medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →arlg.org ↗ - Apple Podcasts
podcasts.apple.com/us/podcast/ep-59-vance-fowler-the-antibacterial-resistance/id1441318864
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - LinkedIn
linkedin.com/in/samantha-keller-422770253
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scholars.duke.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scholars.duke.edu ↗
- Board Certified
Infectious Diseases, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dukehealth.org ↗
Editorial & leadership roles
journal and society appointments- Contact Principal Investigator
NIH Antibacterial Resistance Leadership Group (ARLG), since inception in 2013
2013verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →arlg.org ↗ - Co-founder
International Collaboration on Endocarditis (ICE)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.duke.edu ↗ - Founder
Staphylococcus aureus Bacteremia Group (SABG) registry
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.duke.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →arlg.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.duke.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.duke.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newsinhealth.nih.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →newsinhealth.nih.gov ↗
- "Meet the researcher: Vance Fowler, MD"
profile feature, Duke Department of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.duke.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
John Perfect, MD
Duke University